Literature DB >> 1993221

Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype.

E Berman1, M Adams, R Duigou-Osterndorf, L Godfrey, B Clarkson, M Andreeff.   

Abstract

We examined the effect of tamoxifen (Tmx), verapamil, and daunorubicin (DNR) in two cell lines that displayed the multidrug-resistant (MDR) phenotype and used laser flow cytometry to quantitate intracellular DNR content. In the vinblastine-resistant human lymphoblastic lymphoma cell line CEM-VBL, simultaneous incubation of DNR with Tmx 10 mumol/L or Tmx 50 mumol/L increased intracellular DNR fluorescence in a dose-dependent manner and demonstrated an uptake pattern similar to that seen with DNR and verapamil. Similar results were obtained in the vincristine-resistant human myeloid leukemia cell line HL-60/RV+. Cellular retention of DNR was also measured in both cell lines and results suggested that continuous exposure of the cells to Tmx resulted in higher intracellular DNR content compared with cells resuspended in fresh medium. No effect of Tmx or verapamil was observed in the drug-sensitive parent cell lines CEM or HL-60. Clonogenic experiments were then performed to determine whether Tmx was itself inhibitory to cell growth or whether Tmx potentiated DNR cytotoxicity. Tmx 10 mumol/L did not significantly inhibit either CEM-VBL or HL-60/RV+ cells after a 3-hour exposure followed by culture in methylcellulose. Tmx 50 mumol/L was significantly more inhibitory in both cell lines. However, cells that had been incubated with DNR and Tmx 10 mumol/L demonstrated a marked increment in growth inhibition compared with cells that had been incubated with DNR alone or Tmx 10 mumol/L alone. Based on the data presented here, we suggest that clinical testing of Tmx and DNR be pursued in the setting where MDR may play a role.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1993221

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

Review 1.  Challenges and Potential for Ovarian Preservation with SERMs.

Authors:  Alison Y Ting; Brian K Petroff
Journal:  Biol Reprod       Date:  2015-03-25       Impact factor: 4.285

2.  Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil.

Authors:  G Weinländer; G Kornek; M Raderer; M Hejna; C Tetzner; W Scheithauer
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Tamoxifen paradoxically decreases paclitaxel deposition into cerebrospinal fluid of brain tumor patients.

Authors:  Johnson Chen; Casilda Balmaceda; Jeffrey N Bruce; Michael B Sisti; May Huang; Ying Kuen K Cheung; Guy M McKhann; Robert R Goodman; Robert L Fine
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

4.  Modulation of doxorubicin-toxicity by tamoxifen in multidrug-resistant tumor cells in vitro and in vivo.

Authors:  E Pommerenke; J Mattern; M Volm
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 5.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

6.  A phase I trial of high-dose oral tamoxifen and CHOPE.

Authors:  D C Smith; D L Trump
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 7.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

8.  Variable effects of tamoxifen on human hematopoietic progenitor cell growth and sensitivity to doxorubicin.

Authors:  K E Woods; S Grant; S Yanovich; D A Gewirtz
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

9.  Effect of tamoxifen on mitoxantrone cytotoxicity in drug-sensitive and multidrug-resistant MCF-7 cells.

Authors:  P B Desai; R Bhardwaj; B Damle
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Therapeutic potential of new 4-hydroxy-tamoxifen-loaded pH-gradient liposomes in a multiple myeloma experimental model.

Authors:  Giorgia Urbinati; Davide Audisio; Véronique Marsaud; Vincent Plassat; Silvia Arpicco; Brigitte Sola; Elias Fattal; Jack-Michel Renoir
Journal:  Pharm Res       Date:  2009-12-23       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.